Inserm UMR 702, Université Pierre et Marie Curie-Paris VI, Tenon Hospital, Paris, France.
Int J Exp Pathol. 2011 Jun;92(3):151-7. doi: 10.1111/j.1365-2613.2011.00760.x. Epub 2011 Feb 12.
The need for novel insights into the mechanisms of progression of renal disease has become urgent during the last several years because of the increasing incidence of chronic renal disease worldwide. Independent of the underlying disease, the subsequent progression of renal fibrosis is characterized mainly by both an exaggerated synthesis and abnormal accumulation of extracellular matrix proteins produced by mesenchymal cells within the kidney. These cells are mainly myofibroblasts deriving from a variety of renal cells such as vascular smooth muscle, mesangial, resident stem, tubular epithelial, vascular endothelial cells or pericytes. The appearance of myofibroblasts is a reversible process, as suggested by studies in experimental models showing regression of renal fibrosis during therapy with antagonists and/or blockers of the renin-angiotensin system. An additional factor that can also affect the mechanisms of progression/regression of fibrosis is the plasticity of podocytes controlling glomerular filtration.
在过去的几年中,由于慢性肾脏病在全球范围内的发病率不断上升,因此迫切需要对肾脏疾病进展机制有新的认识。无论潜在疾病如何,随后的肾纤维化进展主要表现为肾脏间质细胞中细胞外基质蛋白的过度合成和异常积累。这些细胞主要是肌成纤维细胞,来源于多种肾脏细胞,如血管平滑肌、系膜、固有干细胞、肾小管上皮细胞、血管内皮细胞或周细胞。实验模型中的研究表明,肌成纤维细胞的出现是一个可逆的过程,在使用肾素-血管紧张素系统拮抗剂和/或阻滞剂进行治疗时,肾纤维化会出现消退。另一个可能影响纤维化进展/消退机制的因素是控制肾小球滤过的足细胞的可塑性。